Last reviewed · How we verify
NCT04454580
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
trial testing Venetoclax in Acute Myeloid Leukemia, Adult in 15 participants. Status unknown.
16 September 2020
Quick facts
| Lead sponsor | Ospedale Maggiore Di Trieste |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 August 2020 |
| Primary completion | 16 September 2020 |
| Estimated completion | 30 September 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Venetoclax (venetoclax) — full drug profile →
Conditions studied
- Acute Myeloid Leukemia, Adult — all drugs for Acute Myeloid Leukemia, Adult →
- Hypomethylating Agents — all drugs for Hypomethylating Agents →
- Venetoclax — all drugs for Venetoclax →
Sponsor
Ospedale Maggiore Di Trieste
Who can join
18 and older, any sex, with Acute Myeloid Leukemia, Adult or Hypomethylating Agents. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective, observational, monocentric study to evaluate the efficacy and safety of the combination of an hypomethylating agent with venetoclax newly diagnosed patients with acute myeloid leukemia ineligible for intensive chemotherapy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
El-Cheikh J, Bidaoui G, Saleh M, Moukalled N, et al · · 2023 · cited 22× · PMID 37071328 · DOI 10.1007/s44228-023-00041-x
Verify or expand the search:
- PubMed search for NCT04454580
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Venetoclax
Trials testing the same drug.
- NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
- NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
Other recruiting trials for Acute Myeloid Leukemia, Adult
Currently open trials in the same condition.
- NCT06652438 — Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML · Phase 3 · recruiting
- NCT06532552 — Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Ne · Phase 2 · recruiting
- NCT06199557 — A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients · Phase 1, PHASE2 · recruiting
- NCT05703126 — Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML · NA · recruiting
- NCT05133882 — A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML · Phase 1, PHASE2 · recruiting
Other Ospedale Maggiore Di Trieste trials
Trials by the same sponsor.
- NCT04419441 — Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04454580 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ospedale Maggiore Di Trieste
- Last refreshed: 16 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04454580.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing